iANTHUS CAPITAL HOLDINGS (ITHUF) Gains from Sales and Divestitures (2022 - 2025)
iANTHUS CAPITAL HOLDINGS's (ITHUF) quarterly Gains from Sales and Divestitures came in at $186757.0 in Q4 2025, down 99.85% year-on-year from $127.0 million in Q4 2024, and up 157.87% quarter-over-quarter from $72423.0 in Q3 2025.
iANTHUS CAPITAL HOLDINGS (ITHUF) Gains from Sales and Divestitures (2022 - 2025) Analysis & Trends
iANTHUS CAPITAL HOLDINGS has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $186757.0 for Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $186757.0, down 99.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $186757.0 (down 99.85% YoY), and the FY2025 annual result was $186757.0, down 99.85% from the prior year.
- Gains from Sales and Divestitures came in at $186757.0 for Q4 2025 at iANTHUS CAPITAL HOLDINGS, up from $72423.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $127.0 million in Q4 2024 to a low of $212.0 in Q1 2025.
- The 4-year median for Gains from Sales and Divestitures is $72423.0 (2025), against an average of $25.7 million.
- Across the five-year window, Gains from Sales and Divestitures jumped 40948.43% in 2023 and tumbled 99.9% in 2024, its largest moves.
- iANTHUS CAPITAL HOLDINGS's Gains from Sales and Divestitures stood at $263155.0 in 2022, then surged by 40948.43% to $108.0 million in 2023, then gained by 17.53% to $127.0 million in 2024, then plunged by 99.85% to $186757.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $186757.0 (Q4 2025), $72423.0 (Q3 2025), and $4945.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | iANTHUS CAPITAL HOLDINGS | - | - | 15.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 186,757.00 |
| Dec 31, 2025 | 186,757.00 |
| Sep 30, 2025 | 72,423.00 |
| Sep 30, 2025 | 72,423.00 |
| Jun 30, 2025 | 4,945.00 |
| Jun 30, 2025 | 4,945.00 |
| Mar 31, 2025 | 212.00 |
| Mar 31, 2025 | 212.00 |
| Dec 31, 2024 | 126.96 Mn |
| Dec 31, 2024 | 126.96 Mn |
| Sep 30, 2024 | 100,295.00 |
| Sep 30, 2024 | 100,295.00 |
| Jun 30, 2024 | 33,951.00 |
| Jun 30, 2024 | 33,951.00 |
| Mar 31, 2024 | 15,974.00 |
| Mar 31, 2024 | 15,974.00 |
| Dec 31, 2023 | 108.02 Mn |
| Dec 31, 2023 | 108.02 Mn |
| Sep 30, 2023 | 97.93 Mn |
| Sep 30, 2023 | 97.93 Mn |